<div id="readability-page-1"><p>Dynamic Advisor Solutions LLC increased its position in  Eli Lilly and Company (NYSE:LLY - Free Report) by 54.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,261 shares of the company's stock after buying an additional 4,692 shares during the quarter. Dynamic Advisor Solutions LLC's holdings in Eli Lilly and Company were worth $10,118,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Several other hedge funds have also added to or reduced their stakes in LLY. Chapin Davis Inc. increased its position in  Eli Lilly and Company by 13.3% in the 3rd quarter. Chapin Davis Inc. now owns 2,222 shares of the company's stock valued at $1,695,000 after acquiring an additional 261 shares during the period.  Whalen Wealth Management Inc. grew its stake in shares of  Eli Lilly and Company by 758.9% in the third quarter. Whalen Wealth Management Inc. now owns 2,551 shares of the company's stock worth $1,947,000 after purchasing an additional 2,254 shares during the last quarter.  Riversedge Advisors LLC raised its position in  Eli Lilly and Company by 61.1% during the 3rd quarter. Riversedge Advisors LLC now owns 472 shares of the company's stock worth $360,000 after purchasing an additional 179 shares during the last quarter.  MFG Wealth Management Inc. lifted its holdings in  Eli Lilly and Company by 44.0% during the 3rd quarter. MFG Wealth Management Inc. now owns 3,020 shares of the company's stock worth $2,304,000 after buying an additional 923 shares during the period.  Finally, Sheets Smith Investment Management bought a new stake in shares of  Eli Lilly and Company in the 3rd quarter valued at about $908,000. 82.53% of the stock is currently owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><p>A number of brokerages have recently issued reports on LLY. Erste Group Bank upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Tuesday, October 14th. Bank of America dropped their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, December 15th. Sanford C. Bernstein  reaffirmed an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a research note on Friday. Daiwa Capital Markets  set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Finally, Leerink Partners  restated an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a report on Thursday. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued  a Buy rating and five have issued  a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $1,141.73.</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p><b>Read Our Latest Stock Analysis on LLY</b></p><h2>Eli Lilly and Company News Roundup</h2><p>Here are the key news stories impacting Eli Lilly and Company this week:</p><ul>   <li><span>Positive Sentiment: </span>Late‑stage trial win — Lilly’s oral GLP‑1 pill orforglipron met the primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial, showing patients who switched from Wegovy or Zepbound kept essentially all prior weight loss; Lilly has submitted orforglipron to the FDA for obesity. <i></i><span>PR Newswire: Lilly's orforglipron helped people maintain weight loss</span></li>    <li><span>Positive Sentiment: </span>Program momentum and regulatory progress — Chugai and other releases highlight positive topline Phase 3 results and Lilly’s FDA filing for orforglipron, reinforcing the company’s leadership in oral GLP‑1s. This raises prospects for rapid commercial adoption if approved. <i></i><span>TipRanks: Chugai highlights positive Phase 3 results</span></li>    <li><span>Positive Sentiment: </span>Analyst upgrades and upside forecasts — Bank of America and other outlets point to improved quality metrics and forecast material upside (BofA cites potential multi‑billion sales for new oral obesity therapies), while Daiwa upgraded LLY — all supportive of higher valuations. <i></i><span>Benzinga: BofA sees room for stock upside</span> <i></i><span>American Banking News: Daiwa upgrade</span></li>    <li><span>Neutral Sentiment: </span>Pipeline depth — Lilly advanced eloralintide into Phase 3, strengthening its obesity/diabetes pipeline beyond orforglipron; this is strategic for longer‑term growth but not an immediate revenue driver. <i></i><span>TipRanks: Lilly advances eloralintide into Phase 3</span></li>    <li><span>Neutral Sentiment: </span>Branding/marketing initiatives — Lilly’s consumer outreach (e.g., Olympics tie‑ins) supports awareness for new therapies but has unclear near‑term financial impact. <i></i><span>MM&amp;M: Lilly debuts video featuring Team USA</span></li>    <li><span>Negative Sentiment: </span>Pricing pressure in Canada — Reuters reported Lilly cut prices of Mounjaro and Zepbound in Canada by ~20% or more, which could compress margins or reduce realized revenue per prescription in markets facing tougher pricing/regulatory scrutiny. <i></i><span>Reuters: Lilly cuts price of diabetes, weight-loss drugs in Canada</span></li> </ul><h2>Eli Lilly and Company Stock Performance</h2><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>NYSE:LLY opened at $1,071.35 on Friday. The company has a fifty day moving average of $960.76 and a 200-day moving average of $830.36. The firm has a market capitalization of $1.01 trillion, a P/E ratio of 52.41, a P/E/G ratio of 1.33 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. </p><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company's revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.  As a group, sell-side analysts anticipate that  Eli Lilly and Company will post 23.48 EPS for the current year. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%. </p><h2>About Eli Lilly and Company</h2> (Free Report)<p>Eli Lilly and Company <span>NYSE: LLY<span></span></span> is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p><h2>Read More</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>What is the Nasdaq? Complete Overview with History</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>Insider Trades May Not Tell You What You Think</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>What is a Microcap Stock? Everything You Need to Know </li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Dynamic Advisor Solutions LLC increased its stake in Eli Lilly by 54.8% in Q3, owning 13,261 shares worth $10.1 million. Other firms also adjusted their positions. Analysts have issued positive ratings, with a consensus of 'Moderate Buy' and a price target of $1,141.73. Eli Lilly's oral GLP-1 pill orforglipron showed positive trial results, boosting prospects for FDA approval and commercial adoption.</p>

Dynamic Advisor Solutions LLC Purchases 4,692 Shares of Eli Lilly and Company $LLY